Centre for Biocatalytic Manufacture of New Modalities (CBNM)

新模式生物催化制造中心(CBNM)

基本信息

  • 批准号:
    EP/S005226/1
  • 负责人:
  • 金额:
    $ 280.16万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2018
  • 资助国家:
    英国
  • 起止时间:
    2018 至 无数据
  • 项目状态:
    未结题

项目摘要

In the ever developing world of pharmaceuticals and treatments of diseases new, more challenging drug targets are being identified that require ever more complex drug molecules. These complex molecules or "New Modalities" bridge the gap between the two existing classes of compounds, small molecules (e.g. Aspirin) and biologics (Antibodies), and are typically larger than the existing small molecules but smaller than traditional biologics. These new classes of molecule offer great promise as novel therapies and indeed many of these medicines are aimed at biological targets that cannot be addressed by traditional either small molecule or antibody derived drugs. The complexity of the new modalities currently results in high cost of manufacture which offers an opportunity to develop lower cost routes to produce these compounds. Small molecule manufacturer has benefited from adopting biocatalysis within manufacturing strategies and has demonstrated the potential for use of these catalysts in wider chemical manufacture, such as reduced waste streams, lower energy costs and reduced costs of goods including solvents. Indeed, the project partners have already generated some early proof-of-concept studies, backed up by a wider literature evidence base suggesting that biocatalysis can be used in the synthesis of these new modalities.Through the partnership of the University of Manchester, AstraZeneca and Prozomix we are bringing together a diverse range of experts that will facilitate the development of new manufacturing strategies to produce these new modalities in an efficient and cleaner manner. The use of biocatalysis has the potential to allow access to chemistries and control of manufacture that are otherwise unavailable to the pharmaceutical manufacturing community. Culminating in lower cost manufacturing that translates into greater access to the next generation of drug for a wider community.
在药物和疾病治疗的不断发展的世界中,新的、更具挑战性的药物靶点正在被确定,这需要更复杂的药物分子。这些复杂分子或“新形态”弥合了两类现有化合物(小分子(例如阿司匹林)和生物制剂(抗体))之间的差距,并且通常大于现有小分子但小于传统生物制剂。这些新的分子类别作为新的疗法提供了巨大的希望,并且实际上这些药物中的许多针对传统的小分子或抗体衍生药物无法解决的生物靶标。目前新模式的复杂性导致高制造成本,这提供了开发较低成本路线以生产这些化合物的机会。小分子制造商从在制造战略中采用生物催化中受益,并已证明这些催化剂在更广泛的化学制造中的潜力,例如减少废物流,降低能源成本和降低包括溶剂在内的商品成本。事实上,项目合作伙伴已经产生了一些早期的概念验证研究,并得到了更广泛的文献证据基础的支持,表明生物催化可以用于这些新模式的合成。通过与曼彻斯特大学的合作,阿斯利康和Prozomix我们汇集了各种各样的专家,将促进新的制造战略的发展,以生产这些新的模式,高效、清洁的方式。生物催化的使用有可能允许获得化学品和控制生产,否则无法获得制药界。最终降低了制造成本,使更广泛的社区更容易获得下一代药物。

项目成果

期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Biocatalysis
  • DOI:
    10.1038/s43586-021-00044-z
  • 发表时间:
    2021-06-24
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Bell, Elizabeth L.;Finnigan, William;Flitsch, Sabine L.
  • 通讯作者:
    Flitsch, Sabine L.
Characterization of native protein structure with ion mobility mass spectrometry, multiplexed fragmentation strategies and multivariant analysis
  • DOI:
    10.1016/j.ijms.2021.116588
  • 发表时间:
    2021-03-26
  • 期刊:
  • 影响因子:
    1.8
  • 作者:
    Black, Rachelle;Barkhanskiy, Alexey;Barran, Perdita E.
  • 通讯作者:
    Barran, Perdita E.
Mechanism of Action of Flavin-Dependent Halogenases.
  • DOI:
    10.1021/acscatal.2c05231
  • 发表时间:
    2022-12-16
  • 期刊:
  • 影响因子:
    12.9
  • 作者:
    Barker, Rhys D.;Yu, Yuqi;De Maria, Leonardo;Johannissen, Linus O.;Scrutton, Nigel S.
  • 通讯作者:
    Scrutton, Nigel S.
Biocatalysis in Drug Design: Engineered Reductive Aminases (RedAms) Are Used to Access Chiral Building Blocks with Multiple Stereocenters.
  • DOI:
    10.1021/jacs.3c07010
  • 发表时间:
    2023-10-11
  • 期刊:
  • 影响因子:
    15
  • 作者:
    Casamajo, Arnau Rue;Yu, Yuqi;Schnepel, Christian;Morrill, Charlotte;Barker, Rhys;Levy, Colin W.;Finnigan, James;Spelling, Victor;Westerlund, Kristina;Petchey, Mark;Sheppard, Robert J.;Lewis, Richard J.;Falcioni, Francesco;Hayes, Martin A.;Turner, Nicholas J.
  • 通讯作者:
    Turner, Nicholas J.
Ion Mobility Mass Spectrometry (IM-MS) for Structural Biology: Insights Gained by Measuring Mass, Charge, and Collision Cross Section.
  • DOI:
    10.1021/acs.chemrev.2c00600
  • 发表时间:
    2023-03-22
  • 期刊:
  • 影响因子:
    62.1
  • 作者:
    Christofi, Emilia;Barran, Perdita
  • 通讯作者:
    Barran, Perdita
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Nicholas Turner其他文献

Pilot randomised controlled trial of school‐based humanistic counselling for psychological distress in young people: Outcomes and methodological reflections
青少年心理困扰校本人文咨询随机对照试验:结果与方法学反思
  • DOI:
    10.1080/14733145.2014.905614
  • 发表时间:
    2014
  • 期刊:
  • 影响因子:
    2.4
  • 作者:
    J. Pybis;M. Cooper;A. Hill;Karen Cromarty;Ruth Levesley;J. Murdoch;Nicholas Turner
  • 通讯作者:
    Nicholas Turner
Mental health support and training to improve secondary school teachers’ well-being: the WISE cluster RCT
心理健康支持和培训以改善中学教师的福祉:WISE 集群随机对照试验
  • DOI:
    10.3310/phr09120
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    0
  • 作者:
    J. Kidger;Rhiannon Evans;S. Bell;H. Fisher;Nicholas Turner;W. Hollingworth;S. Harding;Jillian Powell;R. Brockman;L. Copeland;R. Araya;R. Campbell;T. Ford;D. Gunnell;Richard Morris;S. Murphy
  • 通讯作者:
    S. Murphy
A multi-centre, three-arm, individually randomised, non-inferiority, open trial to compare immediate orally administered, immediate topically administered or delayed orally administered antibiotics for acute otitis media with discharge in children: The Runny Ear Study (REST): study protocol. Trials,
一项多中心、三组、单独随机、非劣效性、开放性试验,比较立即口服、立即局部给药或延迟口服抗生素治疗有分泌物的儿童急性中耳炎:流涕研究(REST):研究
  • DOI:
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    0
  • 作者:
    K. Curtis;M. Moore;C. Cabral;V. Curcin;J. Horwood;R. Morris;Vibhore Prasad;A. Schilder;Nicholas Turner;S. Wilkes;A. Hay;Jodi Taylor
  • 通讯作者:
    Jodi Taylor
Alpelisib plus fulvestrant in emPIK3CA/em-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
阿培利司联合氟维司群治疗 emPIK3CA/雌激素受体突变、激素受体阳性晚期乳腺癌(在 CDK4/6 抑制剂治疗后)(BYLieve):一项 2 期、多中心、开放标签、非对照研究的一个队列
  • DOI:
    10.1016/s1470-2045(24)00673-9
  • 发表时间:
    2024-12-01
  • 期刊:
  • 影响因子:
    35.900
  • 作者:
    Hope S Rugo;Florence Lerebours;Eva Ciruelos;Pamela Drullinsky;Manuel Ruiz-Borrego;Patrick Neven;Yeon Hee Park;Aleix Prat;Thomas Bachelot;Dejan Juric;Nicholas Turner;Nickolas Sophos;Juan Pablo Zarate;Christina Arce;Yu-Ming Shen;Stuart Turner;Hemanth Kanakamedala;Wei-Chun Hsu;Stephen Chia
  • 通讯作者:
    Stephen Chia
P124. Avoiding surgery in breast cancer patients with exceptional Response to neo-adjuvant chemotherapy - ASTARTE Trial
  • DOI:
    10.1016/j.ejso.2019.01.144
  • 发表时间:
    2019-05-01
  • 期刊:
  • 影响因子:
  • 作者:
    Marios Konstantinos Tasoulis;Gillian Ross;Nicholas Turner;Navita Somaiah;Romney Pope;Steve Allen;Peter Barry;Jennifer Rusby;Ashutosh Nerurkar;Peter Osin;Fiona MacNeill
  • 通讯作者:
    Fiona MacNeill

Nicholas Turner的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Nicholas Turner', 18)}}的其他基金

New Synthetic Chaperones to Enhance Protein Activity
增强蛋白质活性的新型合成伴侣
  • 批准号:
    EP/V056085/2
  • 财政年份:
    2023
  • 资助金额:
    $ 280.16万
  • 项目类别:
    Fellowship
Directed Molecular Recognition through Next-Generation Hybrid Molecular Imprinting
通过下一代混合分子印迹进行定向分子识别
  • 批准号:
    EP/V046594/2
  • 财政年份:
    2023
  • 资助金额:
    $ 280.16万
  • 项目类别:
    Research Grant
New Synthetic Chaperones to Enhance Protein Activity
增强蛋白质活性的新型合成伴侣
  • 批准号:
    EP/V056085/1
  • 财政年份:
    2022
  • 资助金额:
    $ 280.16万
  • 项目类别:
    Fellowship
Biocatalytic Manufacturing of Nucleic Acid Therapeutics
核酸治疗药物的生物催化制造
  • 批准号:
    MR/W029324/1
  • 财政年份:
    2022
  • 资助金额:
    $ 280.16万
  • 项目类别:
    Research Grant
Production of Niraparib using Imine Reductases
使用亚胺还原酶生产尼拉帕尼
  • 批准号:
    BB/V003410/1
  • 财政年份:
    2021
  • 资助金额:
    $ 280.16万
  • 项目类别:
    Research Grant
Directed Molecular Recognition through Next-Generation Hybrid Molecular Imprinting
通过下一代混合分子印迹进行定向分子识别
  • 批准号:
    EP/V046594/1
  • 财政年份:
    2021
  • 资助金额:
    $ 280.16万
  • 项目类别:
    Research Grant
Exploration of Linking Chemistry in the Design of Aptamer-Molecularly Imprinted Polymer Hybrids (aptaMIPs)
适配体分子印迹聚合物杂化物 (aptaMIPs) 设计中连接化学的探索
  • 批准号:
    EP/S003339/1
  • 财政年份:
    2019
  • 资助金额:
    $ 280.16万
  • 项目类别:
    Research Grant
Novel Biocatalysts for Improved Routes to an Active Pharmaceutical Ingredient
用于改进活性药物成分路线的新型生物催化剂
  • 批准号:
    BB/N010736/1
  • 财政年份:
    2016
  • 资助金额:
    $ 280.16万
  • 项目类别:
    Research Grant
Imine Reductases: Biochemistry, Engineering and Application
亚胺还原酶:生物化学、工程与应用
  • 批准号:
    BB/M006611/1
  • 财政年份:
    2015
  • 资助金额:
    $ 280.16万
  • 项目类别:
    Research Grant
Biocatalysis & Biotransformation: A 5th Theme for the National Catalysis Hub
生物催化
  • 批准号:
    EP/M013219/1
  • 财政年份:
    2015
  • 资助金额:
    $ 280.16万
  • 项目类别:
    Research Grant

相似海外基金

Sustainable biocatalytic approaches to pyridine and piperidine heterocycles
吡啶和哌啶杂环的可持续生物催化方法
  • 批准号:
    BB/Y004027/1
  • 财政年份:
    2024
  • 资助金额:
    $ 280.16万
  • 项目类别:
    Research Grant
Sustainable Biocatalytic Approaches to Pyridine and Piperidine Heterocycles
吡啶和哌啶杂环的可持续生物催化方法
  • 批准号:
    BB/Y005589/1
  • 财政年份:
    2024
  • 资助金额:
    $ 280.16万
  • 项目类别:
    Research Grant
Collaborative Research: Biocatalytic Alcoholysis of PET in Nonaqueous Solvents for Polymer Recycling
合作研究:PET在非水溶剂中生物催化醇解用于聚合物回收
  • 批准号:
    2309898
  • 财政年份:
    2023
  • 资助金额:
    $ 280.16万
  • 项目类别:
    Standard Grant
Intensification of metallo-enzyme production to unlock sustainable biocatalytic hydrogenation
强化金属酶生产以实现可持续的生物催化氢化
  • 批准号:
    10065700
  • 财政年份:
    2023
  • 资助金额:
    $ 280.16万
  • 项目类别:
    Collaborative R&D
More sustainable biocatalytic imine reductions to chiral amines with hydrogen-driven NADPH recycling operated in batch and continuous flow
通过批量和连续流操作的氢驱动 NADPH 回收,更可持续地生物催化亚胺还原为手性胺
  • 批准号:
    2889869
  • 财政年份:
    2023
  • 资助金额:
    $ 280.16万
  • 项目类别:
    Studentship
Development of Selective Oxidative Biocatalytic Methods
选择性氧化生物催化方法的发展
  • 批准号:
    10606798
  • 财政年份:
    2023
  • 资助金额:
    $ 280.16万
  • 项目类别:
Collaborative Research: Biocatalytic Alcoholysis of PET in Nonaqueous Solvents for Polymer Recycling
合作研究:PET在非水溶剂中生物催化醇解用于聚合物回收
  • 批准号:
    2309899
  • 财政年份:
    2023
  • 资助金额:
    $ 280.16万
  • 项目类别:
    Standard Grant
I-Corps: Catalytic Artificial Self-Assemblies for the Biocatalytic Production of Small Molecules
I-Corps:用于小分子生物催化生产的催化人工自组装体
  • 批准号:
    2335922
  • 财政年份:
    2023
  • 资助金额:
    $ 280.16万
  • 项目类别:
    Standard Grant
Biocatalytic membranes for micro/nano plastic degradation within waste water effluents (BMRex)
用于废水中微/纳米塑料降解的生物催化膜 (BMRex)
  • 批准号:
    10062709
  • 财政年份:
    2023
  • 资助金额:
    $ 280.16万
  • 项目类别:
    EU-Funded
Coflobiopro: Continuous flow biocatalytic process for production of value-added chemicals using magnetic nanoparticle immobilized enzyme microreactors
Coflobiopro:使用磁性纳米颗粒固定化酶微反应器生产增值化学品的连续流生物催化工艺
  • 批准号:
    EP/X032078/1
  • 财政年份:
    2023
  • 资助金额:
    $ 280.16万
  • 项目类别:
    Fellowship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了